Diffuse Large B Cell Lymphoma Refractory Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about Diffuse Large B Cell Lymphoma Refractory clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 3

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLymphoma, B-Cell+6 more
Lyell Immunopharma, Inc.400 enrolled39 locationsNCT07188558
Recruiting
Phase 1

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma RefractoryTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma+8 more
Nathan Denlinger18 enrolled1 locationNCT06209619
Recruiting
Phase 1

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

Follicular Lymphoma ( FL)Diffuse Large B Cell Lymphoma RefractoryPrimary Mediastinal Large B-Cell Lymphoma Refractory+3 more
GenomeFrontier Therapeutics TW Co., Ltd.18 enrolled1 locationNCT06703892
Recruiting
Phase 1

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedEpstein-Barr Virus (EBV) Infection
Thomas Jefferson University30 enrolled1 locationNCT06789159
Recruiting
Phase 2

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
Tianjin Medical University Cancer Institute and Hospital22 enrolled1 locationNCT06570447
Recruiting
Phase 2

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell LymphomaRefractory Transformed B-cell Non-Hodgkin LymphomaDiffuse Large B Cell Lymphoma Refractory+1 more
The Lymphoma Academic Research Organisation65 enrolled13 locationsNCT06271057
Recruiting
Phase 2

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
Zhejiang Cancer Hospital41 enrolled1 locationNCT06086197
Recruiting
Phase 2

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
RenJi Hospital20 enrolled1 locationNCT06033820